Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jacob Gottlieb Adds To Position In Ascendis Pharma A/S (ASND); Armistice Capital Increases Stake In Demand Media Inc (DMD)

Page 1 of 2

Is it a good time to buy shares of Ascendis Pharma A/S (NASDAQ:ASND)Jacob Gottlieb thinks so, since his fund, Visium Asset Management, has significantly increased its holding in the company recently. According to a filing with the Securities and Exchange Commission, Gottlieb has boosted his investment by almost 1 million shares to 1.25 million shares or 5.2% of the company’s common stock. In another filing with the SEC, Steven Boyd‘s Armistice Capital has disclosed the addition of 64,000 shares of Demand Media Inc (NYSE:DMD) to its previous stake. As a result, the fund now has control over 1.03 million shares, which account for 5.2% of the total outstanding shares.

pharma 6

Roughly 10 years old, Visium Asset Management was founded by Jacob Gottlieb, who initially had focused on healthcare and biotechnology stocks, but has diversified his portfolio as his success attracted more capital. Besides healthcare stocks, which account for 54% of the fund’s capital, Visium also holds stocks from the technology and financial sectors in an equity portfolio valued at more than $7 billion. During the second quarter, Gottlieb has made some significant changes to his top holdings, one of them being a massive boost of his stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) – up by 9,000% to 831,400 shares valued at more than $184 million. Visium’s latest 13F filing also shows a 1300% increase of its holding in Aetna Inc (NYSE:AET) to 1.23 million shares worth roughly $156 million.

Jacob Gottlieb
Jacob Gottlieb
Visium Asset Management

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is the small-cap ideas of hedge funds. Our research has shown that the 15 most popular small-cap stock picks among hedge funds outperformed the market by nearly one percentage point per month between 1999 and 2012. We have been forward testing the performance of these stocks since the end of August 2012 and they have returned more than 123% over the ensuing 35 months, outperforming the S&P 500 Index by nearly 65 percentage points (read more details here).

Samuel Isaly of Orbimed Advisors is another fan of Ascendis Pharma A/S (NASDAQ:ASND) and has built a position that amasses 1.44 million shares valued at $25.6 million, according to Orbimed’s latest 13F filing. Peter Kolchinsky’s RA Capital Management is also heavily invested in this stock holding 1.91 million shares worth $33.8 million, this being the biggest position held by a hedge fund in our database. Based in Denmark, Ascendis Pharma A/S (NASDAQ:ASND) has a market cap of $474 million and does not pay a dividend. For the second quarter of 2015, the company posted revenues of €1.9 million ($2.14 million), half the figure reported for the same period in 2014, and a net loss of €0.63 ($0.71) per share. The company’s bottom line was affected by the end of its collaboration with United Therapeutics Corporation (NASDAQ:UTHR) as well as a decrease in revenue from collaborations with other pharmaceutical companies.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!